Stock MRVL MARVEL BIOSCIENCES CORP.
Add to a list
To use this feature you must be a member
Log inSign up

News Marvel Biosciences Corp.

Equities

MRVL

CA57384M1077

Delayed Toronto S.E.
Other stock markets
 09:39:20 2024-04-25 am EDT 		5-day change 1st Jan Change
0.135 CAD 0.00% Intraday chart for Marvel Biosciences Corp. -3.57% +68.75%
Mar. 26 Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 CI
Mar. 25 Marvel Biosciences Announces Positive Interim Results For MB-204 MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024
CI
Marvel Biosciences Announces Positive Interim Results For MB-204
MT
Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Positive Interim Results on Tau Phosphorylation with MB-204
CI
Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204
NE
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB204
CI
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204
NE
Marvel Biosciences Announces Testing MB-204 on Autism by French University
MT
Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Testing MB-204 on Autism by French University
CI
Marvel Biosciences Announces Testing MB-204 on Autism by French University
NE
Marvel Biosciences Announces Closing of Non-Brokered Private Placement
NE
Marvel Biosciences Corp. announced that it has received CAD 0.5 million in funding
CI
Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel
NE
Marvel Biosciences Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023
CI
Marvel Biosciences Corp. Reports Earnings Results for the Full Year Ended July 31, 2023
CI
Marvel Biosciences Invited to Test MB-204 on Autism by French University
NE
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials
CI
Marvel Biosciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023
CI
Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to enter Human Trials
AQ
Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023
CI
Marvel Biosciences Corp. and its Wholly Owned Subsidiary, Marvel Biotechnology Inc. Initiate 4-Week Good Laboratory Practice FDA Investigational New Drug Enabling Dose-Ranging Rat Studies for its Lead Drug Candidate MB-204
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRVL Stock
  4. News Marvel Biosciences Corp.